BGIM
CYTK icon

Boussard & Gavaudan Investment Management’s Cytokinetics CYTK Stock Holding History

Boussard & Gavaudan Investment Management’s Portfolio CYTK Stock Details CYTK Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q4 		– Sell
-18,345
Closed -$555K – 82
2023
Q3 		$555K Buy
18,345
+2,800
+18% +$93.3K 0.06% 73
2023
Q2 		$517K Buy
+15,545
New +$575K 0.05% 82

Other funds holding CYTK

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
RI
RTW Investments New York $10B AUM 135.35% 1-Year Est. Return
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $145B AUM 22.78% 1-Year Est. Return

Boussard & Gavaudan Investment Management's CYTK Position: Q4 2023 in Review

Boussard & Gavaudan Investment Management sold out of Cytokinetics (CYTK) in Q4 2023, closing a stake of 18,345 shares — an estimated $555K sold.

Boussard & Gavaudan Investment Management first reported a position in CYTK in Q2 2023 and held it in 2 quarters. The position peaked at $555K in Q3 2023. 347 funds tracked by Wall St. Rank hold CYTK as of Q4 2023.

  • Boussard & Gavaudan Investment Management reported no remaining Cytokinetics position as of Q4 2023 after selling out during the quarter.
  • Boussard & Gavaudan Investment Management sold 18,345 Cytokinetics shares in Q4 2023, an estimated $555K.
  • Boussard & Gavaudan Investment Management first reported a position in Cytokinetics in Q2 2023 and held it in 2 quarters.
  • Boussard & Gavaudan Investment Management's Cytokinetics position peaked at $555K in Q3 2023.
  • 347 funds tracked by Wall St. Rank held Cytokinetics as of Q4 2023.

Based on Boussard & Gavaudan Investment Management's 13F filing for Q4 2023, filed 13 Feb 2024.